Breaking News Instant updates and real-time market news.

GWPH

GW Pharmaceuticals

$132.68

-0.05 (-0.04%)

07:29
10/04/16
10/04
07:29
10/04/16
07:29

GW Pharmaceuticals reinstated with an Outperform at Leerink

Leerink analyst Paul Matteis resumed coverage of GW Pharmaceuticals with an Outperform rating and $162 price target.

GWPH GW Pharmaceuticals
$132.68

-0.05 (-0.04%)

08/16/16
PIPR
08/16/16
NO CHANGE
Target $147
PIPR
Overweight
GW Pharmaceuticals Epidiolex closer to commercialization, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says that GW Pharmaceuticals is just "one more Phase 3 trial result away" from filing for approval of its Epidiolex for treatment of Dravet Syndrome and Lennox-Gastaut Syndrome refractory seizures, which should happen in the first half of 2017. Schimmer points out that while the company acknowledges that part of the Epidiolex treatment benefit may be coming from a favorable drug interaction, it notes that there is a "meaningful" clinical benefit regardless of background therapy. Schimmer reiterates an Overweight rating and $147 price target on the shares.
08/26/16
08/26/16
UPGRADE

GW Pharmaceuticals upgraded to Hold from Sell at Numis
09/26/16
PIPR
09/26/16
NO CHANGE
Target $147
PIPR
Overweight
GW 'increasingly well positioned' for FDA submission, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says that with three out of three pivotal trials now positive, GW Pharmaceuticals is "increasingly well positioned" for FDA submission next year. Epidiolex continues to demonstrate a "robust and consistent effect in a drug refractory population," Schimmer tells investors in a research note after GW announced top-line data from the second Phase 3 study in Lennox-Gastaut Syndrome. He reiterates an Overweight rating on the shares with a $147 price target.
09/26/16
CANT
09/26/16
NO CHANGE
Target $182
CANT
Buy
GW Pharmaceuticals price target raised to $182 from $165 at Cantor

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.